Background
Methods
Study population
Imaging protocol
Image analysis
Myocardial tagging
Feature tracking (ft)
Volumetric analysis & infarct size quantification
Statistical analysis
Results
Baseline characteristics
Demographics | |||
Age, years | 59.5 ± 11.0 | ||
Male sex, n (%) | 60 (92) | ||
Current/previous smoker, n (%) | 28 (43.1) | ||
Hypercholesterolaemia, n (%) | 15 (23.1) | ||
Hypertension, n (%) | 19 (29.2) | ||
Admission HR, beats per minute | 76 ± 12 | ||
Admission Systolic BP, mmHg | 124 ± 26 | ||
Admission Diastolic BP, mmHg | 75 ± 15 | ||
Peak Creatine Kinase, iU/L | 1064 (418–2588) | ||
Anterior STEMI, n (%) | 30 (46) | ||
Discharge Medications | |||
Aspirin, n (%) | 57 (88) | ||
Clopidogrel, n (%) | 59 (91) | ||
Warfarin, n (%) | 6 (9) | ||
Statin, n (%) | 63 (97) | ||
Beta-blocker, n (%) | 64 (99) | ||
ACEi/ARA, n (%) | 63 (97) | ||
Loop/Thiazide Diuretic, n (%) | 5 (8) | ||
Spironolactone/Eplerenone, n (%) | 7 (11) | ||
CMR Parameters | Baseline | Follow-up |
p-value |
LVEDVI, ml/m−2
| 91.1 (84.5–102.2) | 93.5 (85.0–106) | 0.454 |
LVESVI, ml/m−2
| 53.5 (47.6–65.9) | 47.7 (39.8–61.6) | 0.001 |
LVEF, % | 41.0 ± 8.40 | 47.2 ± 8.46 | <0.001 |
IS, % (of LV mass) | 22.3 (14.5–35.5) | 17.0 (12.3–22.8) | <0.001 |
Cmr findings
Strain at baseline
Correlation of strain with baseline lvef & is
Infarct size (IS) | Ejection Fraction (LVEF) | |
---|---|---|
Tagging (n = 64) | ||
GCS | −0.72** | 0.70** |
Feature Tracking | ||
GCS | −0.61** | 0.71** |
GLS | −0.62** | 0.64** |
Prediction of adverse lv remodelling
Baseline Variable | Prediction of Adverse Remodelling – OR (95% CI, p-value) |
---|---|
GCS (FT), % | 0.92 (0.83–1.03, p = 0.16) |
GLS (FT), % | 0.90 (0.79–1.03, p = 0.14) |
GCS (Tagging), % | 0.88 (0.74–1.05, p = 0.15) |
IS, % | 1.05 (1.01–1.10, p = 0.03)* |